clinical trial · NCT06182969
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
SLEAPG-2575Placebo
brief summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
started
Aug 9, 2024
primary completion
Apr 1, 2026
completion
Dec 1, 2026
last updated
Dec 16, 2025
detailed description
This is a randomized, double-blind, placebo-controlled Phase I/II study. About 40 participants will be recruited to receive either APG-2575 or a placebo, with doses from 200mg up to 800mg.
official title
A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol